Article Text
Miscellaneous
Roflumilast as a treatment for COPD
Statistics from Altmetric.com
Chronic inflammation is the key pathophysiological mechanism in the development of COPD and there is increasing interest in the potential role of novel anti-inflammatory treatments. This phase III multicentre double blind study focuses on roflumilast, an oral phosphodiesterase 4 inhibitor.
1411 patients with stable moderate …